UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934





        Date of Report (Date of earliest event reported): January 8, 2007

                               CELGENE CORPORATION
             (Exact name of registrant as specified in its charter)

           Delaware                         0-16132              22-2711928
--------------------------------- --------------------------- ------------------
(State or other jurisdiction of     (Commission File Number)  (IRS Employer
        incorporation)                                       Identification No.)


         86 Morris Avenue, Summit, New Jersey                      07901
--------------------------------------------------------------------------------
       (Address of principal executive offices)                  (Zip Code)

       Registrant's telephone number, including area code: (908) 673-9000


         -------------------------------------------------------------
         (Former name or former address, if changed since last report.)






Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))








ITEM 8.01     OTHER EVENTS

         On January 8, 2007, Celgene Corporation reviewed its 2006 corporate
achievements and provided its 2007 financial outlook at the JP Morgan 25th
Annual Healthcare Conference. Attached hereto and incorporated herein by
reference as Exhibit 99.1 is the Press Release reviewing such highlights.

         The information in this Report, including the exhibits attached hereto,
is furnished solely pursuant to Item 8.01 of this Form 8-K and shall not be
deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934, or otherwise subject to the liabilities of that section. Furthermore, the
information in this Report, including the exhibits, shall not be deemed to be
incorporated by reference into the filings of the Registrant under the
Securities Act of 1933.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.

           (d) Exhibit 99.1 Press Release dated January 8, 2007.

               These exhibits are furnished pursuant to Item 8.01 and shall not
be deemed to be "filed."



                                   SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                     CELGENE CORPORATION

Date: January 9, 2007                By: /s/ David W. Gryska
                                     --------------------------------------
                                         Name:  David W. Gryska
                                         Title: Chief Financial Officer






EXHIBIT INDEX


EXHIBIT NO.     DESCRIPTION
-----------     -----------

  99.1          Press Release dated January 8, 2007 reviewing the Company's 2006
                achievements and announcing its 2007 financial outlook.